B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
AMRX
AmnealANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+82.5
Score
AI commentary
Primary-source tone is constructive after strong Q2 results, raised guidance, and announced debt repricing. Coverage is positive but sparse, analyst target-count data are incomplete, peers are loose, and social, options, short-interest, and employee-sentiment evidence are unavailable; confidence remains moderate. The anchor price is $17.05 as of 2026-09-08.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystQ2 momentum and raised FY2026 guidance executionMedium impact
Q2 revenue rose 10% to $796 million, adjusted EBITDA rose 12% to $206 million, and management raised 2026 guidance for the second time. Specialty and Affordable Medicines revenue increased 17% and 13%, respectively. [#SEC-8K-2026-07-30]
2026-10-31eventDebt repricing benefit confirmationMedium impact
Amneal announced a 50-basis-point reduction on its $2.084 billion Term Loan B, which should lower future interest costs; completion and the full realized benefit are not confirmed in the available excerpt. [#SEC-8K-2026-07-30]
2027-09-02catalystKashiv biosimilars transaction and regulatory milestonesHigh impact
The pending Kashiv transaction could establish biosimilars as a new growth vertical. Up to $350 million of contingent payments depend on U.S. regulatory milestones for six designated candidates, making value realization dependent on closing, financing, integration, and regulatory execution. [#SEC-8K-2026-07-30] [#8-K-2026-08-10]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology